NVP ADW 742
Cat. No. 5247
Chemical Name: 5-[3-(Phenylmethoxy)phenyl]-7-[tran
Biological ActivityATP-competitive inhibitor of IGF1R (IC50 in the range of 0.1-0.2 μM). Also inhibits c-Kit kinase activity (IC50 in the range of 3-5 μM). Exhibits a synergistic effect with Imatinib, enhancing the sensitivity of multiple small cell lung cancer cell lines to the chemotherapeutics etoposide (Cat. No. 1226) and carboplatin (Cat. No. 2626).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Zhou et al (2011) The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy. Oncol. Rep. 25 1565. PMID: 21455580.
Warshamana-Greene et al (2005) The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin.Cancer Res. 11 1563. PMID: 15746061 .
Warshamana-Greene et al (2004) The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol.Cancer Ther. 3 527. PMID: 15141010.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses NVP ADW 742 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: NVP ADW 742, supplier, NVPADW742, ATP, competitive, inhibitors, inhibits, of, IGF1, receptors, kinases, c-Kit, small, cell, lung, cancer, cell, lines, SCLC, insulin-like, growth, factor-1, receptor, Tocris Bioscience, Insulin and Insulin-like Receptors Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective pan-Trk inhibitor; peripherally restrictedHIOC
Selective TrkB receptor agonist; neuroprotectantAV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinasesCP 724714
Potent and selective ErbB2 inhibitor
April 1 - 5, 2017
Washington, D.C., USA